Skip to main content
Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.32
-0.20 (-2.10%)
At close: Apr 28, 2026, 4:00 PM EDT
9.50
+0.18 (1.93%)
After-hours: Apr 28, 2026, 7:14 PM EDT

Ocular Therapeutix Revenue

In the year 2025, Ocular Therapeutix had annual revenue of $51.95M, down -18.47%. Ocular Therapeutix had revenue of $13.25M in the quarter ending December 31, 2025, a decrease of -22.43%.

Revenue (ttm)
$51.95M
Revenue Growth
-18.47%
P/S Ratio
39.05
Revenue / Employee
$159,849
Employees
325
Market Cap
2.03B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202551.95M-11.77M-18.47%
Dec 31, 202463.72M5.28M9.03%
Dec 31, 202358.44M6.95M13.49%
Dec 31, 202251.49M7.97M18.32%
Dec 31, 202143.52M26.12M150.08%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Sarepta Therapeutics 2.20B
Aurinia Pharmaceuticals 283.06M
Adaptive Biotechnologies 276.98M
Stoke Therapeutics 184.42M
Zymeworks 105.97M
Ascentage Pharma Group International 82.08M
Mesoblast 65.38M
Capricor Therapeutics 11.13M
Revenue Rankings

OCUL News

More News